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Introduction {#sec1}
============

Neural stem cells (NSCs) are found in the ventricular-subventricular zone (V-SVZ) of the lateral ventricles and in the subgranular zone (SGZ) of the hippocampus, the two main neurogenic niches in the adult mammalian brain ([@bib22], [@bib2]). Adult NSCs in the V-SVZ mainly give rise to neurons that populate the olfactory bulbs (OBs) and oligodendrocytes in the corpus callosum. Pioneering work and more recent experiments have demonstrated that NSC divisions generate actively dividing transit amplifying cells (TACs) that form a pool of intermediate progenitors ([@bib18]). These cells further differentiate into proliferating immature neuroblasts (Im. Nbs) that become migrating neuroblasts (Mig. Nbs), which integrate within the OBs to produce functional neurons critical for olfactory memory ([@bib26]).

Quiescent and activated NSCs coexist in adult stem cell niches ([@bib3]). Quiescent NSCs (qNSCs) are slowly dividing cells that can survive antimitotic drugs or irradiation; they can regenerate the V-SVZ, giving rise to new neurons ([@bib18], [@bib15]). In contrast, activated NSCs (aNSCs) are actively dividing and can be eliminated by antimitotic drugs or irradiation ([@bib35], [@bib15]). Both qNSCs and aNSCs have astrocyte-like phenotypes and express glial fibrillary acidic protein (GFAP) and the astrocyte-specific glutamate transporter, GLAST ([@bib18], [@bib9]). However, the combination of markers allowing the isolation of the different prospective subpopulations of V-SVZ cells, including qNSCs, were identified only recently ([@bib35], [@bib7], [@bib15], [@bib13], [@bib31]). Furthermore, only limited knowledge exists on the gene-regulatory networks of quiescent and activated NSCs. Such information is of primary importance in understanding the mechanisms controlling V-SVZ maintenance and regeneration, and its role in diseases.

Among signaling pathways regulating the V-SVZ cell population, the Sonic Hedgehog (SHH) pathway ([@bib8], [@bib21]) was shown to increase cell proliferation and modulate the migration of neuroblasts exiting this niche ([@bib29], [@bib1], [@bib4]). The inactivation of Smoothened (SMO) receptor in cell types expressing the neuroepithelial marker Nestin suggests that this SHH signal transducer is required for maintaining the NSC population ([@bib5]). Activation of this pathway, through the conditional ablation of the main SHH receptor Patched (PTC) in GLAST-expressing cells, leads to a dramatic decrease in neurogenesis and a shift from an asymmetric to a symmetric mode of division in NSCs ([@bib21]). Type B1 NSCs are the primary GLI-expressing population ([@bib25], [@bib37]), and SHH pathway activation is region dependent and more prevalent in the ventral SVZ associated with the production of specific neuronal progeny ([@bib25]). NSCs in the V-SVZ can be also mobilized upon GLI1 inhibition to repair demyelinated lesions ([@bib43]). However, it is not well understood how quiescence is controlled in adult brain neurogenic niches, and the potential role of SHH signaling in its regulation has not been explored.

Here, we combine in vitro and in vivo analysis of both pharmacological and genetic activation of the SHH signaling pathway to explore its potential roles in different steps of neurogenesis. We identified prospective qNSCs, aNSCs, and their progeny from the adult mouse V-SVZ niche using immunofluorescence and fluorescence-activated cell sorting (FACS) techniques ([@bib15], [@bib38], [@bib16]) to characterize and quantify the effects of SHH signaling on the different types of V-SVZ cells. We unveil for the first time the effects of SHH signaling causing an increase in qNSC number and a faster cell cycle in aNSCs. Cell-cycle analysis by video microscopy revealed a shortening of both G~1~ and S-G~2~/M phases of aNSCs in culture. Interestingly, genetic activation of SHH signaling led to a large and progressive accumulation of qNSCs, while after an early increase in the pool of aNSCs the number of aNSCs was drastically reduced and neurogenesis was progressively exhausted. Thus, we report an unsuspected new role for SHH signaling in the regulation of quiescence in the V-SVZ in the adult brain.

Results {#sec2}
=======

Accumulation of qNSCs and Decreased Neurogenesis Following Long-Term Activation of SHH Signaling In Vivo {#sec2.1}
--------------------------------------------------------------------------------------------------------

To gain insight into the role of SHH signaling in vivo specifically in the V-SVZ, we examined the status of the various cell populations after conditional PTC deletion in Glast-expressing cells, which resulted in the activation of the SHH pathway in this neurogenic niche ([@bib21]). For this, we used *Glast-CreERT2*;*Ptc*^*WT/WT*^;*R26R-YFP* offspring (called *YFP-PTC*^+/+^) and *Glast-CreERT2*;*Ptc*^*fl*/*fl*^;*R26R-YFP* (called *YFP-PTC*^−/−^), in which YFP expression is initiated by tamoxifen-mediated activation of the Cre recombinase that permanently marks all the progeny of the recombined cells. We previously observed a progressive decrease in the neurogenic process and a marked accumulation of NSCs in these mice ([@bib21]). However, it is still unknown whether the accumulated NSCs were in their quiescent or activated state.

The progeny of NSCs was traced by following YFP expression in mice treated with tamoxifen and analyzed 6 months later. We observed that the YFP expression level was dramatically affected in coronal brain sections of *YFP-PTC*^−/−^ animals. This was especially obvious in the dorsal part of the V-SVZ enriched in neuroblasts ([Figures 1](#fig1){ref-type="fig"}A, 1A′, 1B, 1B′, 1F, and [S1](#mmc1){ref-type="supplementary-material"}A--S1D) that were associated with the decrease of YFP-positive cells in the granular and glomerular olfactory bulb layers of *YFP-PTC*^−/−^ mice observed previously ([@bib21]). Neuroblasts labeled as DCX^+^ cells ([@bib10]), and TACs labeled as GFAP^−^MASH1^+^ cells ([@bib35]) ([Figures S1](#mmc1){ref-type="supplementary-material"}E and S1F), were dramatically decreased in the YFP-recombined cells ([Figures 1](#fig1){ref-type="fig"}I--1K). These changes were specific to YFP-recombined cells since non-recombined cells showed no differences ([Figures 1](#fig1){ref-type="fig"}I--1K, gray bars).

NSCs were detected using combinations of GFAP/SOX2 ([@bib32], [@bib33]) and GFAP/S100β ([@bib37]) immunolabeling in cells lining the lateral ventricles ([Figures 1](#fig1){ref-type="fig"}C--1E′, [S1](#mmc1){ref-type="supplementary-material"}J, S1K, S1O, and S1P). We found an increase of NSCs (GFAP^+^SOX2^+^ and GFAP^+^S100β^−^ cells) in the YFP^+^ but not in the YFP^−^ fraction ([Figures 1](#fig1){ref-type="fig"}G and 1H, green versus gray bars), indicating that this increase is specific to YFP-recombined cells. These results suggest an accumulation of the NSC population after long-term activation of SHH signaling. To evaluate whether this accumulation was related to qNSCs, aNSCs, or both, we used an accurate YFP/GFAP/MASH1 immunolabeling strategy as GFAP^+^MASH1^+^ cells represent aNSCs ([@bib35]). Interestingly, the population of recombined aNSCs (YFP^+^GFAP^+^MASH1^+^) decreased 6 months after tamoxifen-induced PTC deletion, suggesting that the accumulation of total NSCs is due to qNSCs only ([Figures 1](#fig1){ref-type="fig"}I, [S1](#mmc1){ref-type="supplementary-material"}E, and S1F).

Thus, these data suggest that persistent activation of the SHH signaling pathway in NSCs induces their accumulation in a quiescent state over the long term and a dramatic loss of aNSCs and their progeny in vivo.

SHH Pathway Is Upregulated in qNSCs at Long Term after PTC Deletion {#sec2.2}
-------------------------------------------------------------------

To confirm the results obtained in situ 6 months after PTC deletion we used a rapid and an efficient FACS method, which purifies and identifies the cells present in the mouse V-SVZ using a combination of NSC (LEX) and progenitor cell (EGFR and CD24) markers ([Figure 2](#fig2){ref-type="fig"}) ([@bib12], [@bib19], [@bib35], [@bib15], [@bib17]). This method enables to distinguish qNSCs (LEX^bright^EGFR^−^CD24^−^, hereafter called LEX^bright^) from aNSCs (LEX^+^EGFR^+^CD24^−^, hereafter called LEX^+^EGFR^+^), TACs (LEX^−^EGFR^+^CD24^−^, hereafter called EGFR^+^), Im. Nbs (LEX^−^EGFR^+^CD24^+^, hereafter called CD24^+^EGFR^+^), and Mig. Nbs (LEX^−^EGFR^−^CD24^+^, hereafter called CD24^+^) ([@bib15]). Since LEX-fluorescein isothiocyanate (FITC) antibody used to label NSCs has the same emission wavelength as YFP, we used non-YFP mice: *Glast-CreERT2*;*Ptc*^*WT*/*WT*^ (called *PTC*^+/+^) and *Glast-CreERT2*;*Ptc*^*fl*/*fl*^ (called *PTC*^−/−^). In *PTC*^−/−^ mice, 6 months after tamoxifen-induced PTC deletion, LEX^+^EGFR^+^, EGFR^+^, CD24^+^EGFR^+^, and CD24^+^ populations were dramatically reduced by 59.5%, 58.9%, 51.2%, and 72.2%, respectively compared with *PTC*^+/+^ mice ([Figures 2](#fig2){ref-type="fig"}H--2K). Similarly, we observed a marked decrease in proliferating cells evaluated by Hoechst 33342 DNA content analysis (HO\>2N cells \[[@bib15]\]; [Figures 2](#fig2){ref-type="fig"}A, 2A′, 2D, and 2D′). In contrast, the cell fraction containing qNSCs (LEX^bright^) significantly increased by more than 2-fold ([Figure 2](#fig2){ref-type="fig"}G), which demonstrated that long-term genetic activation of SHH signaling leads to an accumulation of qNSCs. Interestingly, 6 months after PTC deletion the SHH pathway was specifically upregulated in qNSCs. This was concluded from the observation that *Gli1* levels used as a readout of SHH pathway activation were upregulated in qNSCs ([@bib8], [@bib41]), but not in aNSCs, TACs, and Im. Nbs ([Figure S2](#mmc1){ref-type="supplementary-material"}).

Thus, these data demonstrate that long-term genetic deletion of PTC in GLAST-expressing cells results in a specific activation of SHH pathway in qNSCs, resulting in their accumulation in vivo while aNSCs and their progeny are dramatically decreased.

Activation of SHH Signaling In Vivo Induces a Progressive Accumulation of qNSCs and Only a Transient Increase in aNSCs {#sec2.3}
----------------------------------------------------------------------------------------------------------------------

To evaluate the short-term versus long-term effects of PTC deletion in vivo in YFP-PTC^+/+^ versus YFP-PTC^−/−^ mice, we used another FACS method that takes advantage of the GLAST NSC marker, along with EGFR and CD24 ([Figure 3](#fig3){ref-type="fig"}A) ([@bib31]). Indeed, qNSCs were reported to have a GLAST^bright^EGFR^−^CD24^−^ phenotype ([@bib31]), and we found that GLAST^bright^ correlates with LEX^bright^ NSC phenotype in CD24-negative cells ([Figures S3](#mmc1){ref-type="supplementary-material"}A--S3C). Interestingly, short term after PTC deletion, we observed an accumulation of qNSCs (YFP^+^GLAST^bright^EGFR^−^CD24^−^), aNSCs (YFP^+^GLAST^+^EGFR^+^CD24^−^), and TACs (YFP^+^GLAST^−^EGFR^+^CD24^−^), but not their progeny ([Figures 3](#fig3){ref-type="fig"}B--3G). The pool of qNSCs increased continuously over longer time periods (6 months and then 10 months; [Figures 3](#fig3){ref-type="fig"}B--3G), while their progeny, including aNSCs, was progressively exhausted ([Figures 3](#fig3){ref-type="fig"}K--3M and [S4](#mmc1){ref-type="supplementary-material"}). Ten months after PTC deletion, the number of qNSCs increased almost by 8-fold, and was ≈15-fold larger than the aNSC population ([Figures 3](#fig3){ref-type="fig"}H--3J). Strikingly, qNSCs did not seem to differentiate into astrocytes, as no accumulation of mature astrocyte population (GLAST^dim^ expressing cells \[[@bib31]\]) was observed ([Figure S3](#mmc1){ref-type="supplementary-material"}D).

Thus, we prove that PTC deletion in GLAST-expressing cells triggers an initial accumulation of qNSCs, aNSCs, and their immediate progeny as a short-term effect. In contrast, the long-term effect involves accumulation of qNSCs over time while aNSCs and their progeny are progressively exhausted.

SHH Pathway Activation Induces qNSC and aNSC Proliferation {#sec2.4}
----------------------------------------------------------

Next, we evaluated the effects of SHH pathway activation on the proliferation of qNSCs and their progeny. We first performed intraventricular injections of SHH in young adult transgenic fluorescence ubiquitination cell-cycle indicator (FUCCI)-green mice that allow tracking the S-G~2~/M phases with green fluorescence ([@bib42]) ([Figure 4](#fig4){ref-type="fig"}). The number of proliferating qNSCs and aNSCs increased within a short time period (3 days) after intraventricular SHH injections, although the increase in qNSCs was not statistically significant (p = 0.06) ([Figures 4](#fig4){ref-type="fig"}C and 4D). No short-term effect of SHH pathway activation was seen on TACs and neuroblast proliferation ([Figures 4](#fig4){ref-type="fig"}E and 4F). We evaluated long-term effects on cell proliferation with Hoechst 33342 DNA content analysis ([@bib15]) in *YFP-PTC*^+/+^ and *YFP-PTC*^−/−^ mice, 15 days and 10 months after tamoxifen injection ([Figure 5](#fig5){ref-type="fig"}). The pools of proliferating qNSCs and aNSCs expanded 15 days after PTC deletion ([Figures 5](#fig5){ref-type="fig"}A and 5B), contrary to their progeny ([Figures 5](#fig5){ref-type="fig"}C--5E). Long-term activation of the SHH pathway (10 months after PTC deletion) resulted in a complete abrogation of proliferating aNSCs, TACs, Im. Nbs, and Mig. Nbs ([Figures 5](#fig5){ref-type="fig"}G--5J). In contrast, some qNSCs continued proliferating, though to a lesser extent ([Figure 5](#fig5){ref-type="fig"}F).

SHH Increases the Neurosphere-Forming Potential and Shortens the Cell Cycle of Adult aNSCs In Vitro {#sec2.5}
---------------------------------------------------------------------------------------------------

To understand the short-term effect of SHH specifically on the proliferation of aNSCs and not their progeny, we conducted an in-depth study on the cell-cycle dynamics of aNSCs versus TACs and Im. Nbs in vitro. Following FACS with LEX/EGFR/CD24 marker combination in V-SVZ cells from the adult mouse, we previously showed that aNSCs, TACs, and Im. Nbs cells exhibit a capacity to generate neurospheres in vitro, contrary to qNSCs and Mig. Nbs ([@bib15], [@bib17]). Using this method, we observed that SHH (10 nM) treatment increased the potential of aNSCs to form colonies in vitro (number of primary neurospheres generated) by almost 2-fold, but did not increase the potential of TACs or Im. Nbs to form colonies ([Figures 6](#fig6){ref-type="fig"}A--6C).

Moreover, the amount of generated cells, evaluated as neurosphere size from the cell-sorted populations 5 days after plating ([@bib16]), significantly increased for aNSCs after SHH treatment, but not for TACs or Im. Nbs ([Figures 6](#fig6){ref-type="fig"}D--6F). These data suggest that SHH increased the number of cells generated by aNSCs, probably by acting on their cell cycle. We thus used time-lapse video microscopy to test whether activation of SHH signaling would have direct effects on cell-cycle progression of LEX^+^EGFR^+^ and EGFR^+^ cells isolated from young adult mice (2 months of age) ([@bib14], [@bib16], [@bib17]). As expected from the results above, the cell-cycle length of EGFR^+^ cells was not altered by SHH (10 nM) treatment whereas that of LEX^+^EGFR^+^ cells was significantly shortened, from 12.2 ± 1.9 hr to 8.9 ± 2.1 hr (p \< 0.01; [Figure S5](#mmc1){ref-type="supplementary-material"}).

To confirm these results and explore the cell-cycle progression of aNSCs and TACs in detail, we sorted these cell populations from the V-SVZ of adult transgenic FUCCI mice ([@bib42]). Next, we measured the lengths of the G~1~ phase (FUCCI-red fluorescence) and the S-G~2~/M phases (colorless), using time-lapse video microscopy, for cells that completed a full division and underwent at least another subsequent division to exclude any alteration due to cell-cycle exit ([@bib16], [@bib17]). As expected, the lengths of G~1~ and S-G~2~/M phases were similar in non-treated and SHH-treated EGFR^+^ cells ([Figures 7](#fig7){ref-type="fig"}A and 7C), leading to similar cell-cycle lengths ([Figure 7](#fig7){ref-type="fig"}D). In contrast, both G~1~ and S-G~2~/M phases were shortened by almost 1 hr in LEX^+^EGFR^+^ cells treated with SHH (1.1 hr and 0.8 hr, respectively; [Figures 7](#fig7){ref-type="fig"}A and 7B), leading to a shortening of the total cell cycle by 1.9 hr ([Figure 7](#fig7){ref-type="fig"}D) ([@bib34]). Together, these results demonstrate that activation of the SHH pathway in vitro increases aNSC proliferation by shortening both G~1~ and S-G~2~/M phases of their cell cycle. Finally, we investigated whether a pharmacological blockade of the Hh pathway could modify the cell-proliferation effect observed above ([Figures S7](#mmc1){ref-type="supplementary-material"}A--S7K). Treatment with the Smo antagonist MRT-83 (1 μM) ([@bib40], [@bib24]) reduced the number and size of neurospheres produced by aNSCs in vitro ([Figures S7](#mmc1){ref-type="supplementary-material"}A and S7B), mirroring in vitro data with SHH ([Figures 6](#fig6){ref-type="fig"}A and 6D). The number of proliferating qNSCs and aNSCs from the V-SVZ populations was decreased on short-term (3 days) intraventricular MRT-83 injection in FUCCI-green mice, although not significantly for aNSCs ([Figures S7](#mmc1){ref-type="supplementary-material"}G and S7H), probably due to the low basal expression of the pathway in aNSCs ([Figure S2](#mmc1){ref-type="supplementary-material"}).

Together, these data show that activation of the SHH pathway in GLAST-expressing cells triggers an early phase marked by an increase in the proliferation of both qNSCs and aNSCs, leading to an early expansion of their pool. However, long-term activation of the SHH pathway in aNSCs led to progressive depletion of their pool and a collapse of neurogenesis ([Figure S6](#mmc1){ref-type="supplementary-material"}). These findings show that the SHH pathway is essential for maintaining neurogenesis during adulthood by controlling the activation of qNSCs.

Discussion {#sec3}
==========

Self-renewal of NSCs contributes to maintaining neurogenesis in the adult brain throughout life. Neurogenesis is actively involved in odor discrimination and cognitive performance that decrease upon aging ([@bib26], [@bib2]). In the V-SVZ, NSCs also generate oligodendrocytes ([@bib30]). However, the precise molecular mechanisms controlling NSC pool size are not yet well understood. Using newly developed methods that identify the main cell populations of the V-SVZ and a genetic mouse model of SHH activation in NSCs, our study identifies a crucial role of the SHH pathway in the balance between qNSCs and aNSCs in the adult brain, and demonstrates that SHH actively regulates cell quiescence in the V-SVZ.

The recent ability to purify quiescent NSCs from the adult brain and the development of markers enabling their identification in vivo have opened novel avenues for investigating the mechanisms responsible for maintaining these cells in quiescence ([@bib7], [@bib13], [@bib16], [@bib31]). Here we used a combination of two sets of validated markers, LEX, EGFR, CD24 ([@bib15]) and GLAST, EGFR, CD24 ([@bib31]), to prospectively isolate by FACS qNSCs, aNSCs, and their progeny. Following this we analyzed the effects of pharmacological and genetic activation of SHH signaling in these cell populations. We validated the data obtained from the FACS-sorted cells by analyzing the distribution and localization of these cells from *YFP-PTC*^+/+^ *and YFP-PTC*^−/−^ mice, using an accurate immunolabeling strategy (GFAP/MASH1/DCX). This enabled us to selectively identify qNSCs, aNSCs, TACs, and neuroblasts.

Actively dividing B1 cells (aNSCs in our study) were shown to go through three rounds of divisions before differentiating into C cells (referred as TACs in our study) ([@bib39]). However, the mechanisms regulating their behavior both in vitro and in vivo are still not known. Our study takes advantage of the unequivocal identification of aNSCs and TACs to show that cultured aNSCs and TACs have similar cell-cycle lengths (T~c~ ≈ 13 hr), confirming the previous in vivo study ([@bib39]). In addition, we also showed that aNSCs but not TACs proliferate following SHH treatment by reducing their T~c~ by almost 2 hr. A striking observation is that the duration of both G~1~ and S-G~2~/M phases of aNSCs are affected, suggesting that both phases are implicated in the proliferative effects. This specificity at the NSC level is likely due to the degree of SHH pathway activation within the different cell types linked to increased *Gli1* transcription, as we observed in vivo, and might also directly be related to GLI3 repressor activity that is critical for maintaining V-SVZ NSC function in the adult ([@bib37]). We hypothesized that within qNSCs, the level of SHH pathway activation is low to control the balance between quiescence and activation; whereas an increase in SHH signaling deregulates this balance and leads to an expansion of this pool, as we observed in vivo. Our findings corroborate those reported for Hh signaling in the developing vertebrate retina, supporting an increase of transient amplifying progenitor proliferation by speeding up their cell cycles and reducing both their G~1~ and G~2~ phases ([@bib27]).

We observed that genetic activation of SHH signaling induced a progressive increase in qNSC numbers and a marked reduction of the aNSC pool, leading to an almost complete exhaustion of neurogenesis in the long-term and early aging of V-SVZ niches compared with mice displaying basal SHH activation ([Figure S5](#mmc1){ref-type="supplementary-material"}). Interestingly, we identified an initial transient period over the short term when aNSCs are actively proliferating, presumably by shortening both their G~1~ and S-G~2~/M phases, as seen in vitro. In vitro results ([Figures S7](#mmc1){ref-type="supplementary-material"}A and S7B) on isolated cells corroborates in vivo observations, suggesting that the positive effect of SHH pathway activation on aNSC proliferation at short term occurs cell autonomously and is not triggered by microenvironmental changes. During this period, the number of TACs increases. This effect is not linked to a modification of their cell-cycle parameters, as shown in our study, but probably results from the differentiation of a high number of aNSCs that are produced. Migrating neuroblasts are also lowered. This could be explained by the abrogation of the chemoattractive activity that SHH exerts on V-SVZ-derived progenitors through PTC ([@bib4]). Activation of the Hh pathway in NSCs through targeted injections of Ad:GFAPpCre virus in SmoM2-YFP;R26R mice was associated with an alteration of the type of progeny generated in the OB ([@bib25]). There was no evidence of a collapse in neurogenesis but the study was not performed for a long period. The marked reduction of aNSCs over a longer term suggests that qNSC self-renewal is favored at the expense of aNSC production. NSCs appear to have a limited number of divisions ([@bib6]), which could explain that despite the expansion of aNSCs in the period shortly after SHH pathway activation, the low generation of new aNSCs in the long term leads to a significant decrease in their pool. A cell-autonomous defect in aNSCs associated with PTC deletion may also be responsible for this decrease. For example, aNSCs are also programmed to undergo a defined number of divisions prior to differentiation ([@bib14], [@bib39]), and the deletion of PTC in their membranes could alter the number of these divisions. Moreover, recent evidence suggests that aNSCs have limited self-renewal and are exhausted at long term ([@bib11]). The blockade of qNSCs in quiescence provoked by long-term PTC deletion seems to accelerate this phenomenon by reducing the availability of qNSCs needed to sustain neurogenesis over the long term.

Elevated SHH signaling in the dorsal V-SVZ regulates the production of oligodendrocyte progenitor cells in the corpus callosum while SHH signaling in the ventral V-SVZ controls the production of specific neuron subtypes destined for the OB ([@bib45]). We previously observed that PTC deletion in NSCs decreases the ability of precursor cells to give rise to oligodendrocytes ([@bib21]). It would be interesting to evaluate the effect of long-term PTC deletion on the production of specific neurons in the OB ([@bib45]).

*PTC* invalidation in multipotent stem cells of human GFAP-*Cre*;*PTC*^*C*/*C*^ mice during embryogenesis leads to medulloblastomas that develop when the cells have committed to the neuronal lineage ([@bib46]). Our data demonstrate that *PTC* invalidation in NSCs increases the pool of qNSCs over the long term without the development of tumors, which demonstrates that the tumor-suppressor gene function of *PTC* ([@bib23]) depends on the NSC context.

In sum, we uncovered that activation of the SHH pathway increases the pool of qNSCs over a long time period, thus demonstrating that active SHH signaling maintains V-SVZ cell quiescence. This is reminiscent of the recent role attributed to active Hh signaling engaged in an epithelial-mesenchymal regulatory loop to maintain quiescence under normal homeostasis in the adult lung ([@bib36]). Sustained SHH signaling in NSCs presumably occurs during physiological or pathological conditions, for instance, pharmacological activation of Smo using specific small-molecule modulators ([@bib41]), when SHH protein is induced ([@bib20]), or as a result of inactivating PTC or activating Smo mutations. Thus, it will be important to further identify the status of qNSCs and aNSCs in such conditions, as well as determine their effects on neurogenesis, tumor formation, and brain repair. Of note, this accumulated pool of qNSCs has trouble replenishing the SVZ after antimitotic treatment ([@bib21]). Thus, it should be of great interest to address whether the increased pool of qNSCs observed upon SHH activation can be further manipulated in the older animal to restore impaired neurogenesis ([@bib15]) as observed with anti-transforming growth factor β treatment ([@bib38], [@bib16]). Importantly, SHH signaling also regulates NSC mobilization toward demyelinated lesions, and inhibition of GLI1 was shown to mobilize NSCs for remyelination ([@bib43]). Although the phenotype in qNSCs and aNSCs was not reported in this study, it indicates that multiple levels of SHH-GLI signaling regulate more than just proliferation and highlights the importance of determining the state of NSCs and their progeny. Altogether, our data highlight the complex role of the SHH pathway in NSC regulation and its importance for adult neurogenesis, and the need for further understanding of the mechanisms associated with brain tumor formation and brain repair.

Experimental Procedures {#sec4}
=======================

Animals {#sec4.1}
-------

*Glast-CreERT2*;*Ptc*^*WT*/*WT*^;*R26R-YFP* (called *YFP-PTC*^+/+^), *Glast-CreERT2*;*Ptc*^*fl*/*fl*^;*R26R-YFP* (called *YFP-PTC*^−/−^), *Glast-CreERT2*;*Ptc*^*wt*/*wt*^ (called *PTC*^+/+^), and *Glast-CreERT2*;*Ptc*^*fl*/*fl*^ (called *PTC*^−/−^) offspring were obtained as described by [@bib21]. For cell-cycle analysis, transgenic FUCCI chromatin labeling and DNA replication factor 1 (Cdt1)-red and (Geminin)-green mice were used ([@bib42]). Young adult (2--3 months old) C57Bl/6 mice were used for neurosphere and LEX versus GLAST FACS studies. Animal experiments were performed in compliance with the European Communities Council Directive (86/609/EEC) and were approved by our institution\'s ethics committee (11-003).

Tamoxifen Administration, SHH Protein, and MRT-83 Injections {#sec4.2}
------------------------------------------------------------

Tamoxifen (Sigma-Aldrich) was dissolved in corn oil (Sigma-Aldrich) at 10 mg/mL, and 1 mg was injected intraperitoneally twice a day for 5 consecutive days. Animals were killed 15 days, 6 months, or 10 months after the end of tamoxifen application. Male young adult FUCCI Green mice (five animals per group) were stereotactically injected into the right lateral ventricle of human SHHN (Biogen Idec) (5 μL/3 μg) or with the Smo antagonist MRT-83, which blocks Hh signaling in vitro and in vivo (2.5 μL/200 ng), or the vehicle solutions as described previously ([@bib28], [@bib40]). MRT-83 was dissolved in 45% 2-hydroxypropyl-β-cyclodextrin (Sigma) as described by [@bib40]. A batch of SHHN was tested in a well-characterized assay of SHH function, the osteoblastic differentiation of C3H10T1/2 ([@bib41]). A subnanomolar concentration with SHHN (0.3 nM) led to a substantial increase in the response as previously reported ([@bib28]).

Preparation of V-SVZ Cells and FACS {#sec4.3}
-----------------------------------

Lateral ventricle walls containing cells from the V-SVZ were microdissected and dissociated into single-cell suspensions as described by [@bib15], [@bib17]. For DNA content analysis, dissociated cells were incubated with Hoechst 33342 (Sigma), as described by [@bib15]. For mouse cell-surface marker analysis, we used GLAST phycoerythrin (PE) (mouse immunoglobulin G 2a \[IgG2a\]; 1:30, Miltenyi Biotec), CD24 PE/Cy7-conjugated (rat IgG2b; 1:100, Biolegend), CD15/LEX fluorescein isothiocyanate (FITC)-conjugated (mouse IgM; 1:50, BD Biosciences), and Alexa 647-conjugated EGF ligand (1:200, Life Technologies). Cell proliferation status was analyzed by DNA content analysis using Hoechst 33342 ([@bib15]). The cells were transferred into tubes containing a calibrated number of fluorescent beads (Trucount tubes, BD Biosciences), analyzed on an LSRII (BD Biosciences) and sorted on an INFLUX (BD Biosciences), as reported by [@bib15], [@bib17]. Sorting gates were drawn according to FMO (fluorescence minus one) controls. The data were analyzed using FlowJo software (Tree Star).

Immunofluorescence {#sec4.4}
------------------

Mice, under anesthesia, were perfused with 4% paraformaldehyde, and brain sections were cut on the cryostat (14 μm) and processed for immunostaining, as reported by [@bib15]. The primary antibodies used were: mouse anti-GFAP (1:400, Mab3402, Millipore), rabbit polyclonal anti-GFAP (1:400, Sigma), goat anti-DCX (1:200, clone C-18 sc-8066, Santa Cruz Biotechnology), mouse anti-MASH1 (1:100, mAb556604, Becton Dickinson), mouse anti-SOX2 (1:100, mAb6F1.2, Millipore), and rabbit anti-S100B (1:200, mAbZ0311, Dako). Next, slices were incubated with the appropriate secondary antibody (Alexa Fluor series at 1:400, Invitrogen) for 2 hr at room temperature. Staining was replicated on at least three slices from three different parts of the SVZ in three different mice. z Stacks (from 5 to 20 μm thick) containing 5--30 z sections were acquired on a laser-scanning confocal microscope (confocal Leica TCS SP8) with a 40× oil objective (numerical aperture 0.75). Images were analyzed using LAS LF (Bitplane) and reconstructed in ImageJ 1.39t (NIH) and Photoshop CS3 (Adobe).

Cultures of Sorted V-SVZ Cells {#sec4.5}
------------------------------

For neurosphere cultures, sorted cells were plated on poly-D-lysine-coated plates (Sigma) at a density of 1--3 × 10^3^ cells/well in 96-well tissue culture plates (TRP). The culture medium was composed of NeuroCult medium complemented with the proliferation supplement (STEMCELL Technologies), 2 μg/mL heparin, 20 ng/mL EGF, and 10 ng/mL fibroblast growth factor 2. Seven days after plating, the neurospheres were counted and their area measured with ImageJ software. The cultures were incubated at 37°C in a humidified atmosphere containing 5% CO~2~. In vitro treatments with SHH (SHH C24II; R&D 1845-Sh) were done at 10 nM and with MRT-83 at 1 μM.

Live Cell Imaging {#sec4.6}
-----------------

Freshly sorted cells were plated at a density of 1--3 × 10^3^ cells/well in poly-D-lysine-coated 96-well μ-Plate culture plates (Ibidi). Live imaging culture conditions and settings were used as previously described ([@bib16], [@bib17]). Images and time-lapse video were analyzed with ImageJ and NIS-Elements AR.13.00 64-bit software.

RT-PCR {#sec4.7}
------

Recombination efficiency was quantified by real-time PCR using specific primers for *wt PTC*, *PTC*^*flox*^, and *PTC*^*del*^ alleles ([@bib47]). *Gli1*, *Gli2*, and *Gli3* primers were designed based on [@bib44]: *mGli1 forward 5′-TTGGGATGAAGAAGCAGTTG-3′*, *reverse 5′-GGAGACAGCATGGCTCACTA-3′*; *mGli2 forward 5′-ACCCAACACTCAGCAGCAGTAGC-3′*, *reverse 5′-GCTCCGCTTATGAATGGTGATGG-3′*; *mGli3 forward 5′-CAGCTCCACGACCACTGAA-3′*, *reverse 5′-CAGCTCCACGACCACTGAA-3′*. Despite a variation in YFP recombination among GLAST^+^ cells dependent on mouse age, no variation was evidenced between *YFP-PTC*^+/+^ and *YFP-PTC*^−/−^ offspring for a given time point (data not shown). The deletion efficiency in YFP-PTC^−/−^ mice was evaluated to 97.4% in YFP^+^GLAST^+^ and 92.4% in YFP^+^GLAST^−^ populations, respectively (data not shown).

Cell Counting and Statistical Analyses {#sec4.8}
--------------------------------------

Non-parametric tests were conducted using StatView5 software (SAS Institute); the Kruskal-Wallis test associated with Dunn\'s multiple comparison test was used for multiple comparisons, and the Mann-Whitney test was used for two comparisons. The statistical significance was set at p \< 0.05. The data are expressed as mean ± SEM.
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![Long-Term SHH Signaling Activation Induces a Decrease in Neurogenesis and an Accumulation of NSCs Specifically in YFP-Recombined Cells\
Data are derived from *YFP-PTC*^+/+^ (A--E, F--K) versus *YFP-PTC*^−/−^ (A′--E′, F--K) mice 6 months after tamoxifen administration. (A, A′) Immunostaining of coronal brain sections for NSC markers, GFAP and SOX2. (B, B′) YFP expression in the dorsal V-SVZ (C, C′) GFAP^+^SOX2^+^ cells (NSCs; arrowheads) along the ventricle, (D, D′) YFP^+^GFAP^+^S100β^−^ cells (NSCs; arrowheads) along the ventricle, and (E, E′) GFAP^+^SOX2^−^ and YFP^+^GFAP^+^S100β^+^ cells (mature astrocytes; arrowheads) (in E′, S100β and YFP staining is shown in the bottom right corner). (F--K) Quantification of the V-SVZ populations using YFP/GFAP/SOX2, YFP/GFAP/S100β, YFP/GFAP/MASH1, or YFP/GFAP/DCX triple staining. Data are mean ± SEM obtained from brain analyses of four to five mice per phenotype in at least three different slices. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001 (for YFP cell analysis). Scale bars, 100 μm in (A, A′) and 10 μm in (C--E′). See also [Figure S1](#mmc1){ref-type="supplementary-material"}.](gr1){#fig1}

![Long-Term Activation of SHH Signaling Induces an Accumulation of qNSCs and a Decrease in Their Progeny\
Data are derived from *PTC*^+/+^ (A--C, G--K) versus *PTC*^−/−^ (D--K) mice 6 months after tamoxifen administration. (A, D) FACS plots representing V-SVZ proliferating cells (HO-blue is Hoechst 33342). (B, C, E, and F) Labeling of multiple cell populations from the V-SVZ along with the cell-sorting technique (see [Experimental Procedures](#sec4){ref-type="sec"}). (G--K) Quantification of the different V-SVZ populations sorted by FACS using TrueCount microbead-calibrated tubes in *PTC*^+/+^ (black boxes) and *PTC*^−/−^ (colored boxes) mice. Data represent mean ± SEM obtained from the independent analyses of cells isolated from ten mice (A--K) per phenotype, individually for each mouse. ^∗^p \< 0.05, ^∗∗^p \< 0.01. See also [Figures S2](#mmc1){ref-type="supplementary-material"} and [S3](#mmc1){ref-type="supplementary-material"}.](gr2){#fig2}

![A Pool of Quiescent NSCs Progressively Accumulates after SHH Pathway Activation In Vivo while Activated NSC Accumulation Is Transient\
(A) Scheme used for the prospective purification of adult mouse V-SVZ cells by GLAST/EGFR/CD24 flow cytometric-gating strategy (FACS) allowing the identification of quiescent NSCs (qNSCs; GLAST^bright^EGFR^−^CD24^−^), activated NSCs (aNSCs; GLAST^+^EGFR^+^CD24^−^), TACs (GLAST^−^EGFR^+^CD24^−^), immature neuroblasts (Im. Nbs; GLAST^−^EGFR^+^CD24^+^), and migrating neuroblasts (Mig. Nbs; GLAST^−^EGFR^−^CD24^+^) ([@bib15], [@bib31], [@bib17]).\
(B--G) Repartition of YFP cells in neurogenic V-SVZ populations sorted by FACS from *YFP-PTC*^+/+^ and *YFP-PTC*^−/−^ mice 15 days (15 d), 6 months (6 m), and 10 months (10 m) after tamoxifen-induced PTC deletion. Statistical analyses for the charts (PTC^+/+^ versus PTC^−/−^) are presented next to each population in (D--F).\
(H--M) Quantification of the absolute number of qNSCs (blue) and aNSCs (green) populations sorted by FACS using TrueCount microbead-calibrated tubes. Data represent means ± SEM obtained from the independent analyses of cells isolated from five mice per phenotype for each time point, individually for each mouse.\
^∗^p \< 0.05, ^∗∗^p \< 0.01. See also [Figure S4](#mmc1){ref-type="supplementary-material"}.](gr3){#fig3}

![Intraventricular Injection of SHH Increases NSC Proliferation In Vivo at Short Term\
(A) FUCCI-green mice ([@bib42]) that allow tracking the S-G~2/~M phases with green fluorescence received intraventricular injections of SHH (3 μg; AP: ±0 mm, L: −0.85 mm, DV: −2.52 mm) versus Ctrl (vehicle) and FUCCI-green-positive (FG^+^) cells were analyzed by FACS 72 hr after injection, using a FUCCI-green/GLAST-PE/EGF-647/CD24-PEcy7 quadruple staining.\
(B--G) SHH injection provoked an increase in FG^+^ proliferating qNSCs (p = 0.06) and aNSCs (D, E) while no difference was observed for their progeny (C--G).\
Data represent mean ± SEM obtained from the independent analyses of cells isolated from five Ctrl versus five SHH mice, individually for each mouse. ^∗^p \< 0.05.](gr4){#fig4}

![SHH Pathway Activation Stimulates qNSC and aNSC Proliferation at Short Term, but Depletes the Pool of Proliferating aNSCs at Long Term\
Quantification of the number of S-G~2~/M proliferating cells (HO\>2N) in the different V-SVZ populations sorted by FACS using TrueCount microbead-calibrated tubes from *YFP-PTC*^+/+^ (white boxes) and *YFP-PTC*^−/−^ (colored boxes) mice 15 days (15 d; A--E) and 10 months (10 m; F--J) after tamoxifen (Tam)-induced PTC deletion. Cell proliferation status is analyzed by DNA content analysis using Hoechst 33342 ([@bib15]). Data represent means ± SEM obtained from the independent analyses of cells isolated from five mice per phenotype for each time point, individually for each mouse. ^∗^p \< 0.05, ^∗∗^p \< 0.01.](gr5){#fig5}

![SHH Treatment Increases the Neurosphere-Forming Potential of Activated NSCs\
LEX^+^EGFR^+^ (A, D), EGFR^+^ (B, E), and CD24^+^EGFR^+^ (C, F) sorted cells from young adult mouse V-SVZ were plated and then treated with SHH (10 nM) or control buffer (n.t). The neurosphere-forming potential (B--D) was determined as the number of neurospheres formed 7 days after plating, and the amount of cells generated (E, F) was evaluated as the area of the formed neurospheres 5 days after plating. Data represent mean ± SEM obtained from analyses of cells isolated from four to five independent groups of at least five mice. ^∗∗^p \< 0.01; n.s, not significant.](gr6){#fig6}

![SHH Shortens the Cell Cycle of Activated NSCs\
(A) Video microscopy with LEX^+^EGFR^+^ (aNSCs) and EGFR^+^ (TACs) V-SVZ cells sorted by FACS from FUCCI-red mice ([@bib42]) allows tracking the G~1~ phase with red fluorescence, whereas the S-G~2~/M phases are deduced when the red fluorescence switches off. Scale bars, 10 μm.\
(B) The LEX^+^EGFR^+^ cells had shorter G~1~ and S-G~2~/M phases once treated with SHH (10 nM) compared with control treated conditions (n.t).\
(C) SHH treatment did not alter the G~1~ and S-G~2~/M phases in EGFR^+^ cells.\
(D) The LEX^+^EGFR^+^ cells had a shorter total cell-cycle length following SHH treatment, contrary to EGFR^+^ cells. Data represent mean ± SEM obtained from cells isolated from two independent experiments with five mice.\
^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001. See also [Figures S5](#mmc1){ref-type="supplementary-material"} and [S6](#mmc1){ref-type="supplementary-material"}.](gr7){#fig7}
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